Herramientas de evaluación del

beneficioMª Estela Moreno MartínezAdjunta Farmacia, BCOP

Hospital de la Santa Creu i Sant PauBarcelona

1

¿Beneficio?

3

3

BENEFICIO

QoL

SLPSG

TasaRespuesta

4

4

Para el PACIENTE...

CurarseVivir más

Vivir mejor

Medir…

6

6

BENEFICIO

QoL

SLPSG

TasaRespuesta

¿Cuántos meses?

Adyuvanciavs

metastásica¿Escala general vs específica?

¿Estabilización?

¿No pérdida QoL?Efectos adversos tolerables

¿Técnica?

¿HR?

8

8

9

9

Schnniper LE, et al. JCO 2015;33(23):2963-77 Schnniper LE, et al. JCO 2016;34(24):2925-34

10Adyuvancia

Schnniper LE, et al. JCO 2016;34(24):2925-34

11

11

Cherny NI et al. Annals of Oncology 2015;26:1547-73Cherny NI et al. Annals of Oncology 2017;28:2340-66

12

Cherny NI et al. Annals of Oncology 2015;26:1547-73Cherny NI et al. Annals of Oncology 2017;28:2340-66

13

13

14

14

15

15Kiesewetter B, et al. ESMO Open 2020;5;e000611

16

16

17

Cherny NI, et al. Comparative assessment of clinical benefit using the ESMO. Magnitude of clinical benefit scale versión 1.1 and the ASCO value frameworknet health benefit score. JCO 2018;37:336-49

18

Cherny NI, et al. Comparative assessment of clinical benefit using the ESMO. Magnitude of clinical benefit scale versión 1.1 and the ASCO value frameworknet health benefit score. JCO 2018;37:336-49

19

Cherny NI, et al. Comparative assessment of clinical benefit using the ESMO. Magnitude of clinical benefit scale versión 1.1 and the ASCO value frameworknet health benefit score. JCO 2018;37:336-49

20

20

Campolina AG. Value-based medicine in oncology: theimportance of perspective in the emerging value frameworks. Clinics 2018;73(suppl 1):e470s

21

Drug Assesment Framework

21

Ezeife DA, et al. Value assessment of Oncology drugs using a weighted Criterion-based approach. Cancer 2019;0:1-11

Beneficio Clínico

22

22

Ezeife DA, et al. Value assessment of Oncology drugs using a weighted Criterion-based approach. Cancer 2019;0:1-11

23

23

Ezeife DA, et al. Value assessment of Oncology drugs using a weighted Criterion-based approach. Cancer 2019;0:1-11

24

Multi Criteria Decision Analysis

24

Campolina AG. Value-based medicine in oncology: theimportance of perspective in the emerging value frameworks. Clinics 2018;73(suppl 1):e470s

25

25

26mmorenoma@santpau.cat

1